Loading...
Clinical Remission of Severe Crohn's Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
Collen, Lauren V Newburger, Peter E Snapper, Scott B
Collen, Lauren V
Newburger, Peter E
Snapper, Scott B
Citations
Altmetric:
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Case Report
Publication Date
2023-08-28
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy.
Source
Collen LV, Newburger PE, Snapper SB. Clinical Remission of Severe Crohn's Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b. JPGN Rep. 2023 Aug 28;4(4):e356. doi: 10.1097/PG9.0000000000000356. PMID: 38034420; PMCID: PMC10684244.
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1097/PG9.0000000000000356
Permanent Link to this Item
PubMed ID
38034420
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.; Attribution 4.0 International